(Press-News.org) (Barcelona, Spain September 9, 2025, 10:15 a.m. CEST / UTC +2) – A new study presented today reports encouraging long-term survival outcomes from an experimental viral immunotherapy, CAN-2409, in patients with advanced non-small cell lung cancer (NSCLC) who previously failed to respond adequately to immune checkpoint inhibitors (ICI).
The study was presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer.
The phase 2a clinical trial investigated the efficacy of two intratumoral injections of CAN-2409 combined with an oral prodrug (valacyclovir) in patients with unresectable stage III/IV NSCLC, a clinical trial sponsored by Candel Therapeutics. Patients were separated into two cohorts based on their disease status at enrollment: those with stable disease despite ICI and those with progressive disease despite ICI.
Among the 76 patients enrolled, 46 were considered eligible for analysis (per protocol population). At a median follow-up of 32.4 months, median overall survival (OS) for the eligible population was 24.5 months, with 37% of patients still alive more than two years post-treatment. In patients with progressive disease at baseline, median OS was 21.5 months.
“Notably, patients with non-squamous histology demonstrated longer OS than those with squamous histology (25.4 vs. 13.3 months), linked to a significant increase in cytotoxic effector T cells and other favorable immunological changes following treatment,” said Dr. Charu Aggarwal of the Abramson Cancer Center at the University of Pennsylvania.
Systemic immune activation was observed, with abscopal responses seen in 69% of patients with multiple lesions, indicating a robust systemic anti-tumor effect triggered by local treatment.
“This extended follow-up confirms the durable survival benefit of CAN-2409 for patients who otherwise have limited treatment options after failing ICI therapy,” said Dr. Aggarwal. “These results strongly support advancing CAN-2409 into a larger, randomized controlled trial, particularly in patients with non-squamous histology.”
Dr. Aggarwal noted that CAN-2409 continued to show a favorable safety and tolerability profile throughout the extended follow-up period.
About the IASLC:
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 10,000 lung cancer specialists across all disciplines in over 100 countries. The IASLC publishes the Journal of Thoracic Oncology and is committed to advancing research, education, and multidisciplinary collaboration to conquer lung and thoracic cancers worldwide. Learn more at www.iaslc.org.
About the WCLC:
The World Conference on Lung Cancer (WCLC) is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting nearly 7,000 researchers, physicians, and specialists from over 100 countries. The conference promotes awareness, collaboration, and innovation across the spectrum of lung cancer research and care. For more information, visit https://wclc.iaslc.org/.
END
Novel immunotherapy strategy shows promising long-term survival in advanced NSCLC patients with inadequate response to immune checkpoint inhibitors
2025-09-09
ELSE PRESS RELEASES FROM THIS DATE:
Surgery after EGFR TKI shows promise in prolonging progression-free survival in metastatic NSCLC
2025-09-09
(Barcelona, Spain September 9, 2025, 10:15 a.m. CEST / UTC +2) — A randomized Phase II trial from National Taiwan University Hospital reports early evidence that resecting the primary thoracic tumor following EGFR tyrosine kinase inhibitor (TKI) therapy may prolong disease control in patients with metastatic EGFR-mutated non-small cell lung cancer (NSCLC).
The study was presented today at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC).
The trial, which enrolled both oligometastatic and polymetastatic patients, is the first to assess surgical ...
Lung Cancer Europe study highlights communication gaps and need for shared decision-making
2025-09-09
(Barcelona, Spain September 9, 2025, 10:15 a.m. CEST / UTC +2) — A large-scale survey conducted by Lung Cancer Europe (LuCE) has identified critical communication barriers that affect information access, understanding, and shared decision-making among lung cancer patients and caregivers across Europe.
The research was reported at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC).
The study, based on 2,040 valid survey responses from 34 WHO European Region countries in 20 languages, evaluated three key areas: general knowledge about lung cancer, access to information, ...
FANSS study demonstrates feasibility of U.S.-based lung cancer screening in Asian female nonsmokers
2025-09-09
(Barcelona, Spain September 9, 2025, 10:15 a.m. CEST / UTC +2) — Results from the Female Asian Nonsmoker Screening Study (FANSS) highlight the potential value of low-dose CT (LDCT) screening for lung cancer among a growing but underserved population: Asian women with no history of smoking.
The study results were reported today at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC).
FANSS is the first known lung cancer screening program in the U.S. dedicated exclusively to ...
Well-publicized polar geoengineering ideas will not help and could harm, warn experts
2025-09-09
Five well-publicized polar geoengineering ideas are highly unlikely to help the polar regions and could harm ecosystems, communities, international relations, and our chances of reaching net zero by 2050.
This is according to a new assessment, published in Frontiers in Science, which looked at five of the most developed geoengineering proposals currently being considered for use in Antarctica and the Arctic.
The polar regions are home to fragile communities and ecosystems, as well as most of the world’s ice. Technological ‘geoengineering’ approaches have been proposed to delay or address the impacts of climate ...
Racial stereotypes can make us see weapons where they don’t exist
2025-09-09
Unarmed Black civilians are three times more likely to be shot and killed by police officers than unarmed white civilians in the U.S. In tragic cases in recent years, unarmed Black men holding innocuous objects like a wallet, cell phone, or vape pen were killed by police officers because those objects were misidentified as weapons. These split-second fatal mistakes, often under ambiguous and stressful conditions, have sparked urgent debates about their causes and how to fix them.
A new brain-imaging study from researchers at Columbia University ...
“Bottlebrush” particles deliver big chemotherapy payloads directly to cancer cells
2025-09-09
CAMBRIDGE, MA -- Using tiny particles shaped like bottlebrushes, MIT chemists have found a way to deliver a large range of chemotherapy drugs directly to tumor cells.
To guide them to the right location, each particle contains an antibody that targets a specific tumor protein. This antibody is tethered to bottlebrush-shaped polymer chains carrying dozens or hundreds of drug molecules — a much larger payload than can be delivered by any existing antibody-drug conjugates.
In mouse models of breast and ovarian cancer, the researchers found that treatment with ...
New AI tool pinpoints genes, drug combos to restore health in diseased cells
2025-09-09
In a move that could reshape drug discovery, researchers at Harvard Medical School have designed an artificial intelligence model capable of identifying treatments that reverse disease states in cells.
Unlike traditional approaches that typically test one protein target or drug at a time in hopes of identifying an effective treatment, the new model, called PDGrapher and available for free, focuses on multiple drivers of disease and identifies the genes most likely to revert diseased cells back to healthy function.
The ...
Predicting where deadly brain cancer may spread next
2025-09-09
Glioblastoma is a devastatingly effective brain cancer. Doctors can cut it out or blast it with radiation, but that only buys time. The cancer has an insidious ability to hide enough tumor cells in tissue around the tumor to allow it to return as deadly as ever.
Patients diagnosed with glioblastoma survive for an average of 15 months.
What’s needed is a better way of identifying those hidden cancer cells and predicting where the tumor might grow next. Jennifer Munson believes she and her research team at the Fralin Biomedical Research Institute at VTC have developed a tool to do just that.
Their method, described ...
First ever measure of boron in individual cancer cells could revolutionise drug understanding
2025-09-09
A new technique has measured boron in individual cancer cells for the first time, enabling researchers to better understand how drugs act to kill tumours in some cancers.
In a new article in the Journal of Analytical Atomic Spectrometry, a team from the University of Birmingham funded by the Rosetrees Trust have for the first time used a technology to conduct real-time measurement of boron in live tumour cells. The technique, called single-cell ICP-MS, enabled the team to see how and when treatments for head and neck cancers enter and exit tumour cells.
Boron Neutron Capture Therapy (BNCT) is a new form of therapeutic for head and neck cancer that involves ...
Graz researchers discover what stiffens the aorta
2025-09-09
Cardiovascular diseases remain the most common cause of death worldwide. In Europe, they account for over 40 percent of all deaths. However, known risk factors such as high cholesterol levels or high blood pressure cannot fully explain the high mortality rate or the number of cardiovascular diseases. Scientists in Graz have now investigated a new factor that is closely linked to cardiovascular mortality. Elevated levels of the amino acid homocysteine in the blood led to a stiffer and less elastic aorta in an animal model. These findings contribute to the current understanding ...